DiaMedica has met the primary endpoints of safety and tolerability from its recently completed 16-day Phase I multiple ascending dose (MAD) of DM199 in healthy volunteers. DM199 is a recombinant human tissue kallikrein-1 (rhKLK-1) protein and a novel treatment for diabetes and its complications by targeting the Kallikrein-Kinin System. In the Phase I trial of 18 healthy volunteers, DM199 was well-tolerated at all three dose levels and met the primary endpoints of safety and tolerability. DM199 ...